Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > ORGANIZATION
ORGANIZATION
- 35% of Domestic Drug Makers Do Not Conduct First-in-Human Trials in Japan: JPMA Survey
September 5, 2012
- Dr Teshirogi of JPMA Comments on Govt’s Efforts to Promote Regulatory Science; Expresses Concerns About Japan’s Future as Drug-Originating Country
September 5, 2012
- Total Number of MRs Up 4.3% at 63,875, Marking Largest Number in History: MR White Paper
September 5, 2012
- JGA Fails to Achieve Goal of Eliminating “Out-of-Stock” Products Yet Again
August 31, 2012
- Generic Market Share at 25.3% in April-June; Marks Largest Increase: JGA
August 28, 2012
- MHLW Must Present Thorough Explanation If It Insists on Lawmaker-Initiated Bill to Establish 3rd-Party Organization: Yakuhiren
August 28, 2012
- AJD Prioritize Brand Unification of Generic Drugs
August 27, 2012
- Wholesaler’s Operating Profit Margin Improves to 0.31%, Yet Far Cry from FY2007 Level: JPWA
August 10, 2012
- PI Forum to Make Proposals to Promote R&D, Make Pharmaceuticals Japan’s Key Industry: Chairman Toyoda
August 9, 2012
- JPMA Calls for Maintenance or Expansion of R&D Tax Credit System at METI Hearings
August 6, 2012
- 61% of Clinics that Issue Legal Prescriptions Claim Premium for Generic-Name Prescribing: JMA Survey
August 3, 2012
- JMA to Draft COI GLs by End of Year
August 3, 2012
- JMA Executive Board Member Komori Calls For Efforts for “Joint Fight” by Municipalities to Slash IPV Price
July 30, 2012
- 4 Pharmaceutical Associations Issue Joint Statement Calling For Eradicating Online Illegal Drug Sales
July 27, 2012
- EFPIA Submits Opinion Letter to MHLW Calling for Review of Priority Focus on Japanese Companies for Blood Plasma Products
July 27, 2012
- Hiroshima Wholesale FTC Sees “Gradual Effects” in Correcting Labor Services in Cooperation with Pharmacists
July 25, 2012
- 4.5 Bil. Yen Tax Hike Estimated in FY2012 Tax Reform: JPMA
July 17, 2012
- Wholesaler FTC to Make Serious Efforts for Improving “Services of Convenience”
July 13, 2012
- Japan Should Not Copy Foreign HTA Systems: Mr Grainger of PhRMA
July 12, 2012
- JMA Asks Sanofi Pasteur to Lower Price for Inactivated Polio Vaccine
July 9, 2012
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…